Back

Lactate-Driven Heterogeneity of Immune Checkpoint Expression in Breast and Lung Cancer Cell Lines

San-Millan, I.; Martinez, J.; Pickard, S. L.; Hirsch, F. R.; Rivard, C. J.; Brooks, G. A.

2026-01-12 cancer biology
10.64898/2026.01.11.698903 bioRxiv
Show abstract

Tumor-derived lactate is increasingly recognized as an immunosuppressive metabolite within the tumor microenvironment (TME), with emerging evidence highlighting its role beyond metabolism to include epigenetic and immune regulatory functions. While prior studies have primarily focused on individual immune checkpoints, most prominently PD-L1, it remains unclear whether lactate broadly coordinates the expression of multiple immune regulatory pathways across distinct tumor types, particularly in the context of chronic exposure mimicking glycolytic tumors. Here, we investigated the relationship between lactate-producing metabolism and immune checkpoint gene expression in four human cancer cell lines representing breast and lung cancer: MCF7 (estrogen receptor-positive breast), MDA-MB-231 (triple-negative breast), A549 (non-small cell lung), and H82 (small cell lung). By manipulating glucose availability and exposure duration to model acute (6 h) versus chronic (48 h) lactate production, and by pharmacologically inhibiting lactate dehydrogenase (LDH) with oxamate, we quantified extracellular lactate accumulation and assessed transcriptional responses of a panel of immune checkpoints (PD-L1, CD80, CD73, LGALS9, VISTA, PVR, CD47, FGL1, STING) and lactate-associated genes (MCT1, MCT4, LDHA, HCAR1) via qPCR. Chronic high-glucose conditions produced robust, LDH-dependent lactate accumulation and were associated with coordinated, lineage-specific remodeling of multiple checkpoint transcripts, whereas acute exposure induced minimal changes. MDA-MB-231 and A549 cells displayed striking but distinct checkpoint patterns under chronic lactate-producing conditions: MDA-MB-231 cells showed strong co-induction of PD-L1 and CD80, while A549 cells exhibited dominant CD80 induction with modest PD-L1 upregulation. H82 cells upregulated PD-L1 alongside CD73, LGALS9, CD47, and CD80, whereas MCF7 cells demonstrated more modest yet coordinated increases across several checkpoints. Chronic glucose exposure resulted in sustained, LDH-dependent lactate accumulation and coordinated induction of multiple immune checkpoint genes, with distinct lineage-specific patterns, e.g., robust PD-L1/CD80 upregulation in MDA-MB-231 versus CD80 dominance in A549. Unsupervised clustering and principal component analysis revealed that duration of glucose exposure, rather than acute glucose availability, was the primary axis of variation and that MCT4 and HCAR1 clustered with strongly induced checkpoints, consistent with a transcriptional program linking lactate export and sensing to immune regulation. These findings support a model in which lactate acts as an upstream regulator of a broader immune escape program, potentially via mechanisms like lactylation and HCAR1 signaling. This work highlights the limitations of single-checkpoint blockade strategies in solid tumors and underscores the potential of targeting lactate metabolism to enhance immunotherapy efficacy in breast and lung cancers.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cancer Research Communications
46 papers in training set
Top 0.1%
17.4%
2
Breast Cancer Research
32 papers in training set
Top 0.1%
8.4%
3
Cell Reports Medicine
140 papers in training set
Top 0.4%
6.3%
4
Cancers
200 papers in training set
Top 1%
4.8%
5
Scientific Reports
3102 papers in training set
Top 28%
4.3%
6
Nature Communications
4913 papers in training set
Top 36%
4.2%
7
JCI Insight
241 papers in training set
Top 2%
3.1%
8
Cancer Research
116 papers in training set
Top 2%
2.1%
50% of probability mass above
9
Cell Reports
1338 papers in training set
Top 24%
1.7%
10
OncoImmunology
22 papers in training set
Top 0.2%
1.7%
11
Cell Communication and Signaling
35 papers in training set
Top 0.4%
1.7%
12
iScience
1063 papers in training set
Top 16%
1.7%
13
Clinical Cancer Research
58 papers in training set
Top 1%
1.5%
14
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.7%
1.5%
15
Molecular Cancer Therapeutics
33 papers in training set
Top 0.4%
1.5%
16
eBioMedicine
130 papers in training set
Top 2%
1.5%
17
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.3%
18
BMC Cancer
52 papers in training set
Top 2%
1.3%
19
Cell Death Discovery
51 papers in training set
Top 0.9%
1.2%
20
Advanced Science
249 papers in training set
Top 15%
1.1%
21
Communications Biology
886 papers in training set
Top 17%
0.9%
22
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
23
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.8%
0.9%
24
Theranostics
33 papers in training set
Top 1%
0.9%
25
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.3%
0.9%
26
PLOS Computational Biology
1633 papers in training set
Top 22%
0.9%
27
PLOS ONE
4510 papers in training set
Top 64%
0.9%
28
Frontiers in Immunology
586 papers in training set
Top 7%
0.9%
29
Immunology
29 papers in training set
Top 0.8%
0.9%
30
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.7%